Mechanisms of chemotherapy resistance in ovarian cancer.

ABSTRACT: Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (olaparib and niraparib) and one vascular endothelial growth factor inhibitor (bevacizumab) as maintenance therapies for ovarian cancer. In this review, we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.

SUBMITTER: Ortiz M 

PROVIDER: S-EPMC9255249 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature